Cudarolimab is an investigational monoclonal antibody targeting the OX40 receptor (also known as TNFRSF4 or CD134), a co-stimulatory molecule expressed primarily on activated T cells. Its main application lies in immuno-oncology, where it is being developed to enhance anti-tumor immune responses. By binding to OX40, cudarolimab activates T cells, promoting their proliferation, survival, and effector function, particularly in the tumor microenvironment. This mechanism helps overcome immune suppression driven by tumors and may synergize with other immunotherapies such as checkpoint inhibitors. Cudarolimab is currently under clinical evaluation in various solid tumors, including non-small cell lung cancer, melanoma, and other advanced malignancies. It is being studied both as a monotherapy and in combination with agents like PD-1 inhibitors to boost durable immune activation. The goal is to improve clinical outcomes by sustaining T cell responses that can recognize and eliminate cancer cells more effectively.